Bevacizumab, chemotherapy, and RT delay progression: Commentary
Publication
, Journal Article
Friedman, HS
Published in: Oncology Report
September 1, 2009
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2009
Issue
FALL
Start / End Page
6
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S. (2009). Bevacizumab, chemotherapy, and RT delay progression: Commentary. Oncology Report, (FALL), 6.
Friedman, H. S. “Bevacizumab, chemotherapy, and RT delay progression: Commentary.” Oncology Report, no. FALL (September 1, 2009): 6.
Friedman HS. Bevacizumab, chemotherapy, and RT delay progression: Commentary. Oncology Report. 2009 Sep 1;(FALL):6.
Friedman, H. S. “Bevacizumab, chemotherapy, and RT delay progression: Commentary.” Oncology Report, no. FALL, Sept. 2009, p. 6.
Friedman HS. Bevacizumab, chemotherapy, and RT delay progression: Commentary. Oncology Report. 2009 Sep 1;(FALL):6.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2009
Issue
FALL
Start / End Page
6
Related Subject Headings
- Oncology & Carcinogenesis